Skip to main content

Advertisement

Table 2 Anti-CD74 antibody and IgA levels in serum from patients in the SPACE cohort

From: Anti-CD74 antibodies have no diagnostic value in early axial spondyloarthritis: data from the spondyloarthritis caught early (SPACE) cohort

  AxSpA (diagnosis)   Diagnosis and ASAS axSpA criteria AxSpA (diagnosis) confirmed at 1-year follow up
Yes (n = 274) No (n = 286) P value Yes (n = 172) No (n = 238) P value Yes (n = 143) No (n = 64) P value
Anti-CD74 IgG (OD) 0.50 (0.32–0.65) 0.52 (0.38–0.69) 0.15 0.50 (0.30–0.67) 0.52 (0.39–0.70) 0.075 0.43 (0.30–0.58) 0.48 (0.35–0.61) 0.32
Anti-CD74 IgA (U/mL) 19.9 (11.4–30.6) 14.0 (9.3–26.0) <0.001 21.8 (11.6–31.9) 13.5 (8.4–22.3) <0.001 17.6 (9.9–29.0) 13.7 (9.4–23.6) 0.10
Total IgA (g/L) 4.07 (2.90–4.97) 3.37 (2.57–4.66) <0.001 4.06 (3.01–5.03) 3.29 (2.42–4.62) 0.001 4.02 (2.77–4.78) 3.66 (2.43–4.74) 0.14
  1. Results are shown as median (IQR). Axial spondyloarthritis (axSpA) (diagnosis): SPACE participants diagnosed with axSpA by a rheumatologist at baseline; Assessment of SpondyloArthritis International Society (ASAS) axSpA criteria: SPACE participants fulfilling versus not fulfilling the ASAS axSpA criteria at baseline; Diagnosis and ASAS axSpA: SPACE participants diagnosed as having axSpA and fulfilling the ASAS axSpA criteria versus patients not diagnosed as having axSpA and not fulfilling the ASAS axSpA criteria. Missing values were 5.6% for diagnosis of axSpA, 3% for fulfilling the ASAS axSpA criteria, 30.9% for diagnosis and ASAS axSpA criteria and 58.9% for axSpA diagnosis at 1-year follow up
  2. OD optical density